A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1018 participants.

Also called NCT05035082

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,018 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05035082
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05035082. Randomized; no masking; primary purpose treatment. Start 2021-09-01 (actual); primary completion 2025-06-18 (actual). Results posted on 2026-08-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)
Acronym
REALYSE
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
semaglutide
Intervention (Drug)
oral glucose-lowering medications (commercially available)
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct05035082
Content hash
1e5031dd29cd7d5a0c37b70bc71f0c7edb8f0bf5bbaa6a07e2664871eb66f1a1